ArticleDigestive diseases and sciences2025
Dual Functions and Therapeutic Potential of FZD6 in Biliary Atresia.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveBiliary atresia (BA), a severe neonatal cholangiopathy, lacks pharmacological therapies. This study aimed to identify causal genes and therapeutic targets through multi-omics analyses, emphasizing FZD6's role in immune-pathological mechanisms.
methodsMendelian randomization (MR) and GWAS prioritized BA-associated genes. Co-localization, ceRNA network construction, transcriptomic profiling (GSE46960: 64 BA vs 17 controls), and immune infiltration (ssGSEA/CIBERSORT) were conducted. Immunohistochemistry validated FZD6 expression. Molecular docking (CB-Dock2) screened FZD6-targeting drugs.
resultsMR identified four causal genes (GSR, PGAP6, FZD6, FGD4). FZD6 was upregulated in BA tissues (Wilcoxon p = 0.00021) and correlated with immune dysregulation, including central memory CD4 T cells (r = 0.66, **p < 0.01) and T follicular helper cells (r = 0.36, *p < 0.05). Machine learning identified CD56dim NK cells and mast cells as key immune drivers. Immunohistochemistry confirmed FZD6 overexpression in BA bile ducts. Molecular docking identified dexamethasone (- 9.8 kcal/mol) and gomisin N (- 9.5 kcal/mol) as high-affinity FZD6 ligands.
conclusionThis study establishes FZD6 as a novel therapeutic target in BA, linking its dysregulation to immune-mediated bile duct injury. Multi-omics integration advances BA pathogenesis understanding, while drug candidates offer translational potential.
Indexed as
Identifiers
40618286What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.